A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)

PHASE3CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

October 21, 2022

Study Completion Date

October 21, 2022

Conditions
Myasthenia Gravis
Interventions
DRUG

Human normal immunoglobulin G (IgG)

"Study medication is available in the following forms: 5 mL (1 g IgG) in a 5 mL infusion bottle, 10 mL (2 g IgG) in a 10 mL infusion bottle, 20 mL (4 g IgG) in a 20 mL infusion bottle, 50 mL (10 g IgG) in a 50 mL infusion bottle.~Patients will be receiving 2gm/kg (150gm for a 75kg patient) of 20% SCIG (Hizentra) infused over four weeks in a dose escalating manner."

Trial Locations (2)

T6G 2B7

University of Alberta, Edmonton

V5Z 1M9

Vancouver General Hospital - Gordon & Leslie Diamond Health Care Centre, Vancouver

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

CSL Behring

INDUSTRY

lead

University of Alberta

OTHER